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Aim: The novel coronavirus infection (COVID-19), now a worldwide public health concern is 
associated with varied fatality. Patients with chronic underlying conditions like diabetes and 
hypertension have shown worst outcomes. The understanding of the association might be helpful 
in early vigilant monitoring and better management of COVID-19 patients at high risk. The aim 
of the meta-analysis was to assess the association of diabetes and hypertension with severity of 
disease. 
Methods: A literature search was conducted using the databases PubMed and Cochrane until 
March 31, 2020. Seven studies were included in the meta- analysis, including 2018 CIVID-19 
patients. 
Results: Diabetes was lower in the survivors (OR: 0.56; 95%CI: 0.35-0.90; p=0.017; I2: 0.0%) 
and non-severe (OR: 1.66; 95%CI: 1.20-2.30; p=0.002; I2: 0.0%) patients. No association of 
diabetes was found with ICU care. Hypertension was positively associated with death (OR: 0.49; 
95%CI: 0.34-0.73; p=0.000; I2: 0.0%), ICU care (OR: 0.42; 95%CI: 0.22-0.81; p=0.009; I2: 
0.0%) and severity (OR: 2.69; 95%CI: 1.27-5.73; p=0.01; I2: 52.4%). 
Conclusions: Our findings suggest that diabetes and hypertension have a negative effect on 
health status of COVID-19 patients. However, large prevalence studies demonstrating the 
consequences of comorbid diabetes and hypertension are urgently needed to understand the 
magnitude of these vexatious comorbidities.
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1. Introduction
The novel coronavirus (COVID-19) pandemic is now a worldwide public health concern [1] and 
is a progressive public health emergency of global significance [2]. The first case was reported to 
in Wuhan province of China on 31 December, 2019 with unexplained lower respiratory 
infections [3]. The disease has rapid human to human transmission capacity and varied fatality, 
due to acute respiratory distress syndrome (ARDS), multi-organ failure and other serious 
complications [4]. These viruses are termed as the Severe acute respiratory syndrome-
coronavirus-2 (SARS-CoV-2) as it is very similar to the one that caused the SARS outbreak [3]. 
They are a large family of single-stranded RNA viruses (+ssRNA) that can be isolated in 
different animal species [5]. According to recent estimates, 2% of the population is suggested to 
be healthy carriers of Coronavirus and these viruses are responsible for 5% to 10% of acute 
respiratory infections [6]. WHO reports above 2,241,359confirmed cases worldwide since the 
beginning of the epidemic, 152,551deaths covering 213 countries. The epidemiological scenario 
has been changed drastically, as on beginning of the April. Data obtained from the WHO Health 
Emergency Dashboard (April 19, 2020, 5:00 pm CEST) showed countries with most confirmed 
cases are USA (695,353), Spain (191,726), Italy (175,925) Germany (139,897), United Kingdom 
(114,221), France (110,721) followed by epicenter China (84,201). In India, 15,172 cases 
confirmed clinically and, in the laboratory, and 507 deaths are reported [3].
Primarily, the COVID-19 patients have fever, myalgia or fatigue, and dry cough at the time of 
admission [7]. Although most patients are thought to have a favorable prognosis, older patients 
and those with chronic underlying conditions like diabetes, hypertension, coronary heart diseases 
etc. show worse outcomes [8, 9]. Patients with severe illness develop dyspnea and hypoxemia 
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within 1week after onset of the disease, which might quickly progress to ARDS or end-organ 
failure [8]. Various studies have reported the clinical characteristics of patients with covid-19 
who need management in intensive care units. Old age and comorbidities, particularly 
hypertension and diabetes, are believed to be risk factors for disease severity and death in SARS-
Cov-2 infected patients [1, 7, 10]. Another study also reported comorbid hypertension being the 
most common, followed by diabetes and coronary heart disease [11]. Several studies have 
demonstrated higher prevalence of diabetes in COVID-19 patients, however, the effect of the 
prevalence of diabetes on severity of the disease needs further exploration. The understanding of 
the association might be helpful in early vigilant monitoring and better management of COVID-
19 patients at high risk leading to ARDS, organ failure and death. Thus, in this meta-analysis we 
aim to assess the association of diabetes and hypertension with severity of disease. 
2. Materials and methods
This systematic literature review followed the Preferred Reporting Items for Systematic Review 
and Meta-Analysis (PRISMA) guidelines extension for scoping reviews [12].
2.1 Data sources and searches
We searched PubMed, Medline and Cochrane until March 31, 2020 using the keywords 
“COVID-19 and diabetes”, “2019 novel coronavirus and diabetes”, “2019 novel coronavirus and 
hypertension” and “Covid-19 and hypertension”. We also searched grey literature using Google 
Scholar and reference list of eligible articles.
2.2 Inclusion and exclusion
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The studies describing the prevalence of diabetes and hypertension according to disease severity 
were included. We excluded duplicate publications, reviews, editorials, case reports, letters, 
meta-analysis, protocols, studies in language other than English and studies not reporting the 
required data. First author (RP) searched data and screened article for eligibility. Senior author 
(NA) double checked all the included articles and any dispute was resolved by consensus.
2.3 Quality assessment
Two reviewers (RP and NS) assessed the quality of data in the included studies using the 
National Institute of Health (NIH) quality assessment tools [13]. We preferred the NIH tool 
because it is comprehensive and widely accepted for an exhaustive assessment of data quality. 
We rated the overall quality of included studies as good, fair and poor, and incorporated them in 
the meta-analysis results.
2.4 Data extraction
Data were inputted into a standardized data extraction table (Excel) and independently checked 
by a second reviewer (NS) for accuracy. The following variables were extracted: name of the 
first author, year of publication, study design, age, gender, current smoking, number of patients 
in severe and non-severe condition with comorbidities hypertension and diabetes. The included 
studies designated severe group as having respiratory distress, RR ≥ 30 beats/minute in a resting 
state, a mean oxygen saturation of ≤ 93%, and an arterial blood oxygen partial pressure 
(PaO2)/oxygen concentration (FiO2) ≤ 300 mmHg [14].
2.5 Data synthesis
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We performed an exploratory meta-analysis to understand the magnitude and direction of effect 
estimate. Odds ratios (ORs) were calculated and presented with respective 95% confidence 
intervals (CIs). Mantel-Haenszel random-effects meta-analysis using DerSimonian and Laird 
method was used to pool ORs [15]. Heterogeneity between studies was assessed using the χ2-
based Cochran's Q statistic (p<0.1 considered as the presence of heterogeneity) and I-squared (I2) 
statistics (>50% representing moderate heterogeneity) [15]. Forest plot was produced and studies 
were grouped according to their design. Publication bias was not assessed as a total number of 
studies were less than ten [15].
3. RESULTS
3.1 Search results 
The systematic search yielded a total of 105 publications. Out of 105 studies 40 studies were 
found using the keyword” COVID-19 and diabetes”, 16 studies with keyword “2019 novel 
coronavirus and diabetes”, 33 studies with the term “Covid-19 and hypertension”, and 14 studies 
with keyword “2019 novel coronavirus and hypertension”.  Two studies were found from other 
sources. After removing duplicates, 53 articles were found to be potential publications for 
screening. After the application of predefined inclusion and exclusion criteria, a total of seven 
studies were included for the meta-analysis.
3.2 Study characteristics
All the included studies were conducted in China. The prevalence of diabetes and hypertension 
were reported in survivors and non-survivors in two studies, ICU care and non-ICU care patients 
in two studies, while the prevalence of diabetes and hypertension in severe and non-severe 
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patients was reported in three studies. Among the seven included studies, three were cohort 
studies [11, 14,16], while four were case-series [1, 7, 10, 17]. The studies enrolled a total of 2018 
patients, including 1175 males and 840 females. The demographic characteristics of the subjects 
included in these studies are provided in Table 1.
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Groups No. of 
patients
Age Sex Current 
smoker
Male Female




Total 274 62.0 (44.0-70.0) 171 
(62)
103 (38) 12 (4)
Deaths 113 68.0 (62.0-77.0) 83 (73) 30 (27) 7 (6)
Recovered 
patients
161 51.0 (37.0-66.0) 88 (55) 73 (45) 5 (3)
P value NA NA NA
Zhou et al, 
2020
Cohort Total 191 56·0 (46·0–67·0) 119 
(62)
72 (38) 11 (6)
Deaths 54 69·0 (63·0–76·0) 38 (70) 16 (30) 5 (9)
Recovered 
patients





Total 41 49·0 (41·0–58·0) 30 (73) 11 (27) 3 (7)
ICU care 13 49·0 (41·0–61·0) 11 (85) 2 (15) 0
Non-ICU 
care
28 49·0 (41·0–57·5) 19 (68) 9 (32) 3 (11)
P value 0·60 0·24 0·31




Total 138 56 (42-68) 75 
(54.3)
63 (45.7) NA










Cohort Total 140 57 (25-87) 71 
(50.7)
69 (49.3) 2 (1.4)
Non-
severe
82 51.5 (26-78) 38 
(46.3)
44 (53.7) 0 (0)
Severe 58 64 (25-87) 33 
(56.9)
25 (43.1) 2 (3.4)
P value < 0.001 0.219 0.17




Total 135 47 (36-55) 72 
(53.3)
63 (46.7) 9 (6.7)
Non-
severe
95 44 (33-49) 52 
(54.7)
43 (45.3) 8 (8.4)
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Severe 40 56 (52-73) 21 
(52.5)
19 (47.5) 1 (2.5)
Guan et al, 
2020














Severe 173 52.0 (40.0–65.0) 100 
(57.8)
73 (42.2) 29 
(172)^^^
Data is presented as Median (IQR) or number (%).
No., number; ICU, intensive care unit; NA, not available; IQR, inter quartile range.
*Out of 1096, **Out of 923, ^Out of 1085, ^^Out of 913, ^^^Out of 172 
3.3 Quality assessment
We assessed the quality of data in the included studies using the NIH quality assessment tools. 
The quality assessment indicated that most included studies were of acceptable quality. All the 
papers clearly stated the research question or objective, the study population was clearly 
specified and defined and all the subjects were selected from the same or similar populations. 
The detailed result of the quality assessment is provided in Supplementary File.
3.4 Association between diabetes and disease severity
For death outcome, two studies (one case-series and one cohort) qualified for inclusion in 
quantitative analysis. The pooled estimate (OR: 0.56; 95% CI: 0.35-0.90; p=0.017; I2: 0.0%) 
suggested that diabetes was significantly lower in the survivors (Figure 2a). The analysis of two 
case series suggested that diabetes was not statistically associated ICU care (OR: 0.78; 95% CI: 
0.06-9.34; p=0.842; I2: 75.9%) with substantial heterogeneity in individual study estimates 
(Figure 2b). Further, the pooled estimate of two cohort studies and one case-series suggested 
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significant association between diabetes and severity (OR: 1.66; 95% CI: 1.20-2.30; p=0.002; I2: 
0.0%) (Figure 2c).
3.5 Association between hypertension and disease severity
For death outcome, two studies (one case-series and one cohort) qualified for inclusion in 
quantitative analysis. The pooled estimate (OR: 0.49; 95% CI: 0.34-0.73; p=0.000; I2: 0.0%) 
suggested that hypertension was significantly lower in the survivors (Figure 3a). Similarly, the 
analysis of two case series suggested that hypertension was statistically associated with ICU care 
(OR: 0.42; 95% CI: 0.22-0.81; p=0.009; I2: 0.0%) (Figure 3b). Further, the pooled estimate of 
two cohort studies and one case-series suggested significant association between hypertension 
and severity (OR: 2.69; 95% CI: 1.27-5.73; p=0.01; I2: 52.4%) (Figure 3c).
4. DISCUSSION
Recent evidence on SARS-CoV-2 suggest that the presence of comorbidities increase mortality 
risk in COVID-19 patients. Diabetes is one the most important components to predict adverse 
outcomes [18]. Thus, the present meta-analysis was conducted to assess the association of 
diabetes with disease severity in COVID-19 patients. The present meta-analysis was based on 
data from 7 studies on COVID-19 patients. The present meta-analysis demonstrated that the 
prevalence of diabetes is lower in survivors than in non-survivors of COVID-19 patients. 
However, there was no difference in diabetes prevalence in patients requiring or not requiring 
ICU care. Additionally, a positive association between diabetes and disease severity was found. 
Several studies have demonstrated higher prevalence of diabetes in COVID-19 patients, 
however, the effect of the prevalence of diabetes on severity of the disease needs further 
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exploration. A recent meta-analysis on the comorbidities suggested diabetes as one of the most 
prevalent comorbidities (8±6, 95% CI 6-11%), in COVID-19 patients. However, no significant 
difference was found in diabetes between severe and non-severe group [19]. Another similar 
meta-analysis demonstrated the pooled prevalence of diabetes to be 7.87% (95%CI 6.57%-
9.28%) [20]. A meta-analysis reported the proportions of diabetes in patients with COVID-19 to 
be 9.7%. The incidences of diabetes were about two folds higher in ICU/severe cases than in 
their non-ICU/severe counterparts [18]. A retrospective study showed that 85.54% of severe 
patients had diabetes or cardiovascular diseases, which was significantly higher than that of the 
mild group [21]. A case-series reported 58% COVID-19 patients to have comorbid diabetes 
mellitus [22].
Although the pathophysiology involved in this comorbidity remains unexplained, several 
hypotheses have been suggested. Blood glucose level is suggested to play an essential role in the 
pathogenesis of infectious diseases. The immune system of diabetes patients might be altered by 
the abnormal blood glucose level, resulting in dysregulation and reduced responses of immune 
components. Consequently, these patients are susceptible to SARS-CoV-2 and various other 
types of bacteria [21]. Another hypothesis states that, human pathogenic coronaviruses, SARS-
CoV and SARSCoV-2 bind to their target cells through angiotensin-converting enzyme 2 
(ACE2), which is expressed by epithelial cells of the lung, intestine, kidney, and blood vessels. 
The expression of ACE2 is significantly increased in diabetes patients, being treated with ACE 
inhibitors and angiotensin II type-I receptor blockers. Use of thiazolidinediones and ibuprofen 
can also be increased ACE2. Consequently, the increased expression of ACE2 would facilitate 
infection with COVID-19 [23].
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The present meta-analysis showed that hypertension is lower in survivors than in non-survivors 
of COVID-19 patients. Additionally, a positive association of hypertension with disease severity 
and ICU care was found. A recent meta-analysis demonstrated hypertension to be the most 
prevalent comorbidity (17±7, 95% CI 14-22%) in COVID-19 patients. Additionally, higher risk 
with hypertension was found in the severe group compared to those in Non-severe group, (OR 
2.36, 95% CI: 1.46-3.83) [19]. According to another meta-analysis, the pooled prevalence of 
hypertension in people infected with SARS-CoV-2 were estimated as 16.37% (95%CI: 10.15%-
23.65%) [20]. A meta-analysis reported the proportions of hypertension in patients with COVID-
19 to be 17.1%. The incidence of hypertension were about two folds higher in ICU/severe cases 
than in their non-ICU/severe counterparts [18]. Hypertension is treated with ACE inhibitors and 
ARBs, which results in an upregulation of ACE2 and SARSCoV-2 binds to their target cells 
through ACE2. Consequently, the increased expression of ACE2 in hypertension patients 
receiving ACE inhibitors would facilitate infection with COVID-19 [23].
Diseases such as hypertension, diabetes and cardiovascular diseases, and their susceptibility 
conditions, may be linked to the pathogenesis of COVID-19. Chronic diseases share several 
standard features with infectious disorders, such as the proinflammatory state, and the 
attenuation of the innate immune response. Patients having any comorbidity had poorer clinical 
outcomes than those without any comorbidity. A higher number of comorbidities correlated with 
poorer clinical outcomes. A thorough assessment of comorbidities may help establish risk 
stratification of patients with Covid-19 upon hospital admission [16, 19]. Major gaps in the 
knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of 
disease need fulfilment by future studies [7]. There are several limitations that needs to be 
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mentioned. The number of studies included in the meta-analysis is small. Substantial 
heterogeneity was observed among the studies. Additionally, case-series were included in the 
present meta-analysis. Although we did an extensive search, we may have inadvertently missed 
relevant studies. Exclusion of studies in languages other than English may have resulted in 
missing of relevant studies.
To conclude, our findings showed that comorbid diabetes and hypertension have a negative 
effect on health status of COVID-19 patients. However, large prevalence studies demonstrating 
the consequences of comorbid diabetes and hypertension are urgently needed to understand the 
magnitude of these vexatious comorbidities. Extensive studies are required to fill the major gaps 
in understanding of the disease to establish risk stratification of the patients.
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Figure 1 Flow diagram of the number of studies screened and included in the meta-analysis.
Figure 2 Association of diabetes and covid-19 in a) survivors and non-survivors, b) ICU and 
non-ICU care, and c) severe and non-severe.
Figure 3 Association of hypertension and covid-19 in a) survivors and non-survivors, b) ICU and 
non-ICU care, and c) severe and non-severe.
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